We thus used RNA-based CD30-specific aptamers for selective cell targeting [33,34,35], an ALK oncogene-specific siRNA for gene therapy [36,37], and the chemotherapeutic drug doxorubicin (Dox) in a DNA intercalation form to kill targeted lymphoma cells, as described in the Materials and Methods Section. This evidence concerns the gene ALK and lymphoma.